In this issue:
Effect of partners on chemotherapy outcomes
Primary chemotherapy for borderline resectable/locally advanced pancreatic ductal adenocarcinoma
Anamorelin for gastrointestinal cancer patients with cachexia
Aflibercept + mFOLFOX6 induction chemotherapy in high-risk rectal adenocarcinoma
Impact of adjuvant oxaliplatin chemotherapy duration on colon cancer outcomes
Pembrolizumab in treatment-refractory MSI-H/dMMR metastatic colorectal cancer
Very high PD-L1 expression and response in NSCLC
Risk of gastric adenocarcinoma in metformin users
Disease-free survival as a surrogate for overall survival
Tumour deposits in rectal cancer after neoadjuvant therapy
Please login below to download this issue (PDF)